Simbrinza

Per mL Brinzolamide 10 mg, brimonidine tartrate 2 mg

Decrease of elevated IOP in adults w/ open-angle glaucoma or ocular HTN for whom monotherapy is insufficient.

Adult & elderly 1 drop in affected eye(s) bd.

Hypersensitivity to brinzolamide, brimonidine tartrate, or sulphonamides. Concomitant use of MAOIs; antidepressants which affect noradrenergic transmission (eg, TCAs & mianserin). Patients w/ severe renal impairment; hyperchloraemic acidosis. Neonates & infants <2 yr.

Do not inj or ingest. Not recommended in patients w/ narrow-angle glaucoma. Careful monitoring of patients w/ compromised corneas (eg, patients w/ DM or corneal dystrophies) & patients wearing contact lenses. Risk of ocular allergic reactions; delayed ocular hypersensitivity reactions; systemic effects (hypersensitivity reactions, including SJS & TEN). Discontinue use in case of signs of serious reactions or hypersensitivity. Reports of acid-base disturbances. Contains benzalkonium Cl. Remove contact lens prior to instillation & wait at least 15 min before reinsertion. Administer at least 5 min apart if using >1 topical ophth medicinal product. Concomitant use w/ antihypertensives &/or cardiac glycosides. Caution in patients w/ severe or unstable & uncontrolled CV disease; depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans; risk of renal impairment; hepatic impairment. Moderate influence on the ability to drive & use machines. May impair ability of elderly patients to perform tasks requiring mental alertness &/or physical coordination. Not recommended during pregnancy & in women of childbearing potential not using contraception. Should not be used by breast-feeding women. Safety & efficacy in childn & adolescents 2-17 yr have not been established. Not recommended in childn ≥2 yr (especially 2-7 yr &/or weighing <20 kg) because of the potential for CNS-related side effects.

Somnolence, dizziness, dysgeusia; eye allergy, keratitis, eye pain, ocular discomfort, blurred vision, abnormal vision, ocular hyperaemia, conjunctival blanching; dry mouth.

TCAs may blunt the ocular hypotensive response. Possible additive or potentiating effect w/ CNS depressants (eg, alcohol, barbiturates, opiates, sedatives or anaesth). Reduced pulse & BP w/ concomitant use of antihypertensives &/or cardiac glycosides. Potential additive effect on known systemic effects of carbonic anhydrase inhibition w/ oral carbonic anhydrase inhibitor & topical brinzolamide. Inhibited metabolism of brinzolamide w/ CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clotrimazole, ritonavir, troleandomycin). Use w/ caution in patients taking medicinal products affecting metabolism & uptake of circulating amines (eg, chlorpromazine, methylphenidate, reserpine, SNRIs). Use w/ caution when initiating concomitant adrenergic receptor agonists or antagonists (eg, isoprenaline, prazosin).

Antiglaucoma Preparations

S01EC54 - brinzolamide, combinations ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.

P₁S₁S₃